Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from PolyPid ( (PYPD) ) is now available.
PolyPid Ltd. has announced its upcoming Annual and Extraordinary General Meeting of Shareholders, scheduled for June 25, 2025. The meeting will address several key issues, including the re-election of board members, approval of compensation policies, and an option grant for the CEO. Notably, Jacob Harel, the current chairman of the board, will not seek re-election, ending his tenure since 2017. This transition marks a significant change in leadership, potentially impacting the company’s strategic direction and stakeholder interests.
The most recent analyst rating on (PYPD) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on PolyPid stock, see the PYPD Stock Forecast page.
Spark’s Take on PYPD Stock
According to Spark, TipRanks’ AI Analyst, PYPD is a Neutral.
PolyPid’s score reflects significant financial challenges, including consistent losses and negative equity. While the company’s clinical advancements and financing efforts are promising, they are not sufficient to offset the financial risks. The stock exhibits neutral technical indicators and an unattractive valuation, limiting its appeal to investors.
To see Spark’s full report on PYPD stock, click here.
More about PolyPid
PolyPid Ltd. operates in the pharmaceutical industry, focusing on the development and commercialization of innovative, locally administered therapies to improve surgical outcomes. The company is known for its proprietary PLEX technology, which is designed to deliver drugs directly to the surgical site, enhancing efficacy and reducing systemic side effects.
Average Trading Volume: 18,896
Technical Sentiment Signal: Sell
Current Market Cap: $28.64M
For a thorough assessment of PYPD stock, go to TipRanks’ Stock Analysis page.